$NXTC has been mentioned 4 times over the past 12 months by 2 distinct FinTwit voices, with the first mention on April 1, 2026, and the most recent on July 14, 2026. Jacob Plieth (@jacobplieth) is the most active voice discussing the stock, accounting for 4 mentions, while Adam Feuerstein (@adamfeuerstein) contributed 1 mention. The biotech category represents the primary discussion focus for this ticker.

In June 2026, @jacobplieth highlighted concerns about $NXTC's CDH6-targeting ADC SIM0505, noting it "looks toxic at active dose" after a 45% share decline, and subsequently commented on PROC responses at the 8.0mg/kg dose being "too toxic to take into phase 2." More recently, @adamfeuerstein discussed a reverse merger transaction involving the company, describing it as "basically a new long-acting I&I company" with a $320 million private placement and an oral, weekly IL-23 drug from Hansoh.